Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Induction of calstabin-2 binding to PKA-phosphorylated RyR1 in mouse skeletal muscle at >50 nM
Assay data:1 Active, 1 Tested
SummaryCompounds, ActiveRelated BioAssays by Target
Induction of calstabin-1 binding to PKA-phosphorylated RyR1 in mouse skeletal muscle at >50 nM
Induction of calstabin-2 binding to RyR1 in mouse skeletal muscle at >50 nM
Induction of calstabin-1 binding to RYR1 in myocardial infarction-induced heart failure calsiabin2-/- mouse soleus muscle at 0.5 mg/kg/day dosed via implantable osmotic minipumps
Inhibition of of PKA-induced RyR1 phosphorylation in myocardial infarction-induced heart failure mouse soleus muscle at 0.5 mg/kg/day dosed via implantable osmotic minipumps
Induction of calstabin-1 binding to RYR1 in myocardial infarction-induced heart failure wild type mouse soleus muscle at 0.5 mg/kg/day dosed via implantable osmotic minipumps
Cardiotoxicity in haploinsufficient FKBP12.6 expressing mouse assessed as reduction in non-sustained ventricular tachycardia at 1 uM under testing exercise followed by epinephrine injection relative to control
Assay data:1 Tested
Summary
Induction of calstabin-1 binding to RyR1 in mouse skeletal muscle at >50 nM
Normalization of RYR1 in myocardial infarction-induced heart failure mouse soleus muscle assessed as decrease in average channel close dwell time
SummaryRelated BioAssays by Target
Normalization of RYR1 in myocardial infarction-induced heart failure mouse soleus muscle assessed as increase in average channel open dwell time
Antiarrhythmic activity in haploinsufficient FKBP12.6 expressing mouse assessed as reduction in sustained ventricular tachycardia at 1 uM under testing exercise followed by epinephrine injection relative to control
SummaryCompounds, Active
Improvement in soleus muscle fatigability in myocardial infarction-induced heart failure calstabin2-deficient knockout mouse at 0.5 mg/kg/day relative to control
Improvement in soleus muscle fatigability in myocardial infarction-induced heart failure mouse model at 0.5 mg/kg/day relative to control
Induction of normalization of RYR1 function in mdx dystrophin deficient mouse soleus muscle assessed as decrease in average channel close dwell time at 1 uM
Induction of normalization of RYR1 function in mdx dystrophin deficient mouse soleus muscle assessed as increase in average channel open dwell time at 1 uM
Induction of normalization of RYR1 function in mdx dystrophin deficient mouse soleus muscle assessed as increase in channel open probability at 1 uM
Reduction in RyR2 channel opening probability in FKBP12.6 deficient mouse in the presence of epinephrine injection followed by exercise testing
Reduction in RyR2 channel opening probability in haploinsufficient FKBP12.6+/- mouse in the presence of epinephrine injection followed by exercise testing
Reduction in PKA-phosphorylation of RyR2 in FKBP 12.6 deficient myocardial infarction-induced heart failure mouse model at 0.5 mg/kg/hr after 28 days post myocardial infarction
Reduction in PKA-phosphorylation of RyR2 in myocardial infarction-induced heart failure mouse model at 0.5 mg/kg/hr after 28 days post myocardial infarction
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on